



















# Bio-Link Licensing Portfolio Q4 2017

	Program	Indication	Modality	Mechanism of Action	Owner	Discovery	Lead Generation	Pre-Clinical	Phase I	Phase II
Therapeutics	<a href="#">KT009</a>	Chronic back pain	Growth factor	Regeneration of IVD tissue	Kunovus Technologies					
	<a href="#">Xanamem™</a>	Alzheimer's disease	SM	Lowers CNS cortisol	Actinogen Medical					
	<a href="#">Irofulven</a>	Castration resistant prostate cancer / Hepatic cell carcinoma	SM & companion diagnostic	Cytotoxicity	Oncology Venture					
	<a href="#">LiPlaCis®</a>	Metastatic breast cancer	Cisplatin liposome formulation	LiPlaCis® technology for targeted delivery	Oncology Venture					
	<a href="#">APO010</a>	Multiple myeloma / Metastatic breast cancer	Peptide & Companion diagnostic	Immuno-oncology	Oncology Venture					
	<a href="#">CNC118</a>	Immuno-oncology	Allogeneic cancer vaccine	Melanoma vaccine to stimulate immune T-cells	Cancure					
	<a href="#">CNC332</a>	Oncology	SM	Mitochondrial complex II inhibitor	Cancure					
	<a href="#">CNC225</a>	Immuno-oncology	SM	Galectin inhibitor	Cancure					
	<a href="#">CD5-2</a>	Immuno-oncology	Oligo nucleotide	Selective vascular endothelial-cadherin modulator	Centenary Institute & Mirrx Therapeutics					
	<a href="#">Dynamain inhibitor</a>	Immuno-oncology	SM	Dynamain II GTPase inhibitor	University of Queensland, CMRI, & University of Newcastle					
	<a href="#">Dynamain inhibitor</a>	Refractory epilepsy	SM	Dynamain I GTPase inhibitor	Children's Medical Research Institute & University of Newcastle					
	<a href="#">Ring Stabilizer™</a>	Chronic kidney disease	SM	Activates dynamain GTPase activity	Children's Medical Research Institute & University of Newcastle					
	Program	Technology			Owner	Prototype	Proof of Concept	Clinical Validation	Product Registration	
Medical Devices	<a href="#">Realm System</a>	3-dimensional joint loading assessment device			The Realm System					
	<a href="#">SureStep™</a>	Step training system for fall prevention in elderly people			Neuroscience Research Australia					
	<a href="#">EVestG™</a>	Objective assessment of neurological diseases and optimisation of CNS drug trials			Neural Diagnostics					
	Program	Technology			Owner	Preclinical Proof of Concept		Clinical Proof of Concept		
Platform Technologies	<a href="#">iVectors</a>	Custom protein expression vectors			GenoFab					
	<a href="#">Blockmir Technology</a>	Oligonucleotide blockmir technology platform for drug discovery			Mirxx Therapeutics					

	Program	Indication	Modality	Mechanism of Action	Owner	Discovery	Lead Generation	Pre-Clinical	Phase I	Phase II
Research Tools	<a href="#">Akimba</a>	Murine model for diabetic retinopathy			Lions Eye Institute					

LEGEND: AP-1: Activator Protein-1; GM: Genetically modified; PAL: Phenylalanine ammonia-lyase ; PKU: Phenylketonuria ; SCHN: Sydney Children's Hospitals Network; SM: Small molecule; CMRI: Children's Medical Research Institute;